Larry Brown
Chief Scientific Officer Noveome Biotherapeutics
Dr. Larry R. Brown is a visionary leader in biomedical innovation with a distinguished career spanning academic, clinical, and industry settings. He earned his Sc.D. in Biochemistry and Bioengineering from MIT under the mentorship of Robert Langer and trained in the surgical research laboratory of Judah Folkman at Boston Children’s Hospital. As Chief Scientific Officer and Executive Vice President at Noveome Biotherapeutics, he has led the translation of ST266, a novel amnion-derived cell secretome, from preclinical research through clinical trials for neurodegenerative and systemic inflammatory diseases. Previously, as Vice President of Research at Baxter Healthcare and in leadership roles at several biotech startups, he directed pioneering work in protein, peptide, and nucleic acid microsphere delivery technologies. In addition to his industry accomplishments, Dr. Brown mentors early-stage academic entrepreneurs as an Catalyst advisor at the MIT Deshpande Center for Technological Innovation. He is the author of more than 50 peer-reviewed publications, holds numerous patents, and is a frequent speaker at international scientific forums.
Seminars
- Exploring how intranasal delivery can bypass the blood-brain barrier to enable direct access to the central nervous system
- Examining the opportunities and challenges of developing potent biologics for neurodegenerative diseases including Alzheimer’s, Parkinson’s, and ALS
- Understanding the scientific, clinical, and commercial considerations needed to drive broader adoption of nose-to-brain therapeutics
- Identify the critical scientific, translational, and clinical evidence gaps that remain before nose-to brain delivery can achieve widespread regulatory acceptance and commercial adoption
- Understand what regulators still need to see regarding reproducibility, biodistribution, imaging, clinical outcomes, and direct CNS exposure before confidently supporting nose-to-brain claims
- Debate whether current preclinical models, analytical tools, imaging technologies, and translational approaches are sufficient to predict human outcomes and support development decisions
- Separate genuine scientific progress from industry hype by examining which technologies, pathways, and approaches are producing meaningful evidence versus those that continue to face significant validation challenges
